News

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...
Moderna has withdrawn the Biologics License Application (BLA) for mRNA-1083, a combination vaccine against seasonal influenza and SARS-CoV-2, after ...
According to Makary and Prasad, the US’s adoption of a “one-size-fits-all” guidance for COVID-19 vaccination departs from ...
Nucleoside reverse transcriptase inhibitors appear to be neuroprotective, thus lowering the incidence of Alzheimer dementia.
The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was ...
AD109 is a once daily pill that consists of aroxybutynin, an antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor.
Jivi is not indicated for use in patients less than 7 years old due to a greater risk for hypersensitivity reactions and/or loss of efficacy. The Food and Drug Administration (FDA) has expanded ...
No gynecological malignancies were seen, while expected incidence was 0.26 or greater for all cancer types. HealthDay News — Short-term testosterone use among transmasculine and gender diverse ...
The vaccine is expected to be commercially ready for the 2025-2026 COVID-19 season. The Food and Drug Administration (FDA) has approved Nuvaxovid ™ (COVID-19 Vaccine, Adjuvanted) for active ...